Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
HOME > BUSINESS
BUSINESS
- Patient Enrollment for Tepotinib PII Begins in Japan: Merck Serono
October 13, 2016
- 69.2% Response Rate Seen in Lenvatinib, Pembrolizumab Combination: Eisai
October 13, 2016
- Daiichi Sankyo Kicks Off Quizartinib Global PIII for 1st-Line AML
October 13, 2016
- Takeda to Tighten R&D Focus, Strengthen Collaboration with Outside Parties; Main Challenge Will Be Financial
October 13, 2016
- Pfizer’s Cancer Research Selected for Feasibility Study under AMED Program; Applied Jointly with Mie Univ. and Other Partners
October 13, 2016
- Interview: Teva Exec Says Takeda JV Can Grow Profit despite Generic Price Declines
October 12, 2016
- Takeda, UK’s Crescendo Cut Collaboration Deal on Cancer Therapeutics
October 12, 2016
- Daiichi Sankyo’s ADC DS-8201a Well-Tolerated in PI
October 12, 2016
- There Will Be Consolidation in Japan Generic Space: Teva Exec
October 11, 2016
- Teva-Takeda JV Eyes Top Spot in Off-Patent Drug Market: CEO
October 11, 2016
- Astellas Suits Actavis Elizabeth in US over Myrbetriq Patent
October 11, 2016
- Companion Diagnostics for Opdivo, Keytruda Pending Approval: Agilent Japan Head
October 7, 2016
- Santen, RIKEN, FBRI Sign Drug Discovery Deal for Retinal Disease
October 7, 2016
- Teikoku Seiyaku, Mitsubishi Tanabe Hook Up on Sales of Anti-Allergy Agents
October 6, 2016
- GHIT Fund to Invest 1.1 Billion Yen in Development of Neglected Disease Drugs
October 6, 2016
- Eurofarma Gets Latin American Rights to Eisai’s Cancer Candidate Farletuzumab
October 5, 2016
- Daiichi Sankyo, AgonOx Ink Immuno-Oncology Research Collaboration
October 5, 2016
- Marc van der Heijden to Lead Allergan Japan
October 4, 2016
- Daiichi Sankyo Launches Large-Scale Research in Elderly NVAF Patients
October 4, 2016
- Constipation Drug Delivers Positive PIII Data in Japan: EA Pharma, Mochida
October 4, 2016
ページ
Japan’s pharmaceutical policy appears to be entering a new phase. The government’s newly approved honebuto policy and growth strategy both…
A few weeks ago, I had coffee with a very talented executive. Let’s call him Kenji. He has a great job, a big salary, and a solid team. But he was unhappy. He felt bored and wanted a new challenge.…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…